Anesthesia And Respiratory Devices Market Size and Trends

The Global Anesthesia and Respiratory Devices Market is estimated to be valued at USD 56.12 Bn in 2025 and is expected to reach USD 84.50 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 6% from 2025 to 2032.

Key Takeaways of the Anesthesia and Respiratory Devices Market:

By product type, the anesthesia devices segment is expected to contribute the highest share of the market with 42.1% in 2025.
By end user, the hospitals and clinics segment is expected to contribute the highest share of the market with 33.2% in 2025.
By gender, the male segment is expected to contribute the highest share of the market with 52.3% in 2025.
North America is expected to top the global market with 42.3% share in 2025, followed by Asia Pacific with 25.5% share in 2025.

Market Overview:

The anesthesia and respiratory devices industry is witnessing positive growth trends over the past few years. There is increasing adoption of anesthesia machines owing to the rising number of surgical procedures globally. Technological advancements in respiratory care devices with integrated software solutions are further supporting the market growth. Growing prevalence of respiratory diseases due to rising air pollution levels and increasing global geriatric population are key factors driving the demand for respiratory devices. Furthermore, favorable government initiatives for promoting effective respiratory care are expected to boost the anesthesia and respiratory devices market during the forecast period. However, high cost of innovative respiratory devices may hinder the market growth to some extent.

Anesthesia and Respiratory Devices Market Concentration By Players

To learn more about this report, Request sample copy

Key Developments:

In November 2024, Mindray, a medical device company, introduced significant upgrades to its A7 and A5 anesthesia systems as part of the A Series Anesthesia lineup. These enhancements feature advanced technologies designed to improve anesthesia precision, boost patient safety, and enhance perioperative efficiency.
In May 2024, Masimo, a leader in innovative medical technologies, partnered with Medable Inc., a leading healthcare technology company, to incorporate its MightySat Rx pulse oximeter into Medable’s evidence-generation platform. This integration supports eight large-scale pharmaceutical trials focused on breast and lung cancer, involving over 3,000 patients across 25 countries.
In April 2024, Royal Philips, a global leader in health technology, announced plans for a new R&D center within its Healthcare Innovation Center (HIC) in Maharashtra, India. Set to be operational within two years, the facility will focus on sleep & respiratory care, precision diagnosis, image guided therapy, and monitoring.
In June 2022, Medtronic and GE Healthcare, both renowned for healthcare innovation, received U.S. FDA 510(k) clearance and CE Mark approval to integrate Microstream capnography and INVOS regional oximetry into GE’s CARESCAPE precision monitoring platform. This advancement enhances the ability to monitor respiratory compromise and predict perioperative complications.

Top Strategies Followed by Global Anesthesia and Respiratory Devices Market Players

Established players focus heavily on R&D investments to innovate high-performance products
- For instance, in October 2024, Finland-based respiratory health innovator, WellO2, introduced its latest breathing exercise device at the Pharmacy Show 2024. Designed for individuals seeking drug-free solutions to improve respiratory function, the device offers proven benefits for managing chronic conditions such as asthma, sleep apnea, COPD, and other breathing disorders.
Mid-level companies are addressing unique market needs by focusing on specific medical conditions, developing specialized devices that cater to particular patient populations
- For instance, in June 2024, Savara Inc., a clinical-stage biopharmaceutical company, focused on rare respiratory diseases, presented the top-line results from the pivotal Phase 3 IMPALA-2 clinical trial. This trial assessed the efficacy and safety of molgramostim , an inhaled form of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF).
Small players like Ventec Life Systems target niche markets with unique products tailored for specific respiratory conditions, such as portable ventilators for home use. Small-scale companies are adopting cutting-edge technologies. For instance, companies like OxyGo are utilizing advanced oxygen delivery systems to remain competitive in the market.

Emerging Startups - Anesthesia and Respiratory Devices Industry Ecosystem

In the area of innovative technologies, startups are developing smart ventilators integrated with sensors and AI algorithms to optimize breath delivery. Some examples include Anthropic, which created an AI-powered closed-loop ventilator able to learn patient needs. These advanced ventilators could personalize treatments and reduce physician workload.
Regarding sustainable solutions, companies like AirXT and Innovo Technology develop recycled or eco-friendly respiratory products. AirXT makes ventilator filters from bioplastics while Innovo produces anesthesia machines with reduced e-waste. Their contributions may help lower costs and cut the industry's carbon footprint over time.
Startups also address unique niche markets. BioIntelliSense focuses on compact remote monitoring devices for ambulatory and pediatric patients. Other examples are Anthropic and Innovotech, which created transport ventilators tailored for ground and aeromedical evacuation. Through specialized solutions, these emerging companies expand the reach of respiratory and anesthesia care globally.